Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Zentralbl Chir ; 135(6): 508-15, 2010 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-21154207

RESUMO

BACKGROUND: Pleural effusions and ascites are associated with distressing symptoms like dyspnoea, intestinal obstruction, vomiting, nausea and pain. In patients with underlying malignancy, the prognosis is limited to few months. After unsuccessful medical treatment, surgical and experimental palliative treatment is indicated. METHODS: This review includes a systematic analysis of surgical, experimental and palliative options. RESULTS: In patients with pleural effusions, thoracocentesis, permanent percutaneous drainage, thoracoperitoneal shunts as well as pleurodesis by tubes or thoracoscopy are available, which will be used depending on the re-expansion of the lung. In patients with ascites, paracentesis is able to control acute symptoms. For long-lasting treatment, portosystemic shunts (TIPS) are favourable for patients with liver cirrhosis. Peritoneovenous shunts can be implanted by laparotomy, but are correlated with high rates of complications and occlusions. In patients with malignancy, pleural effusions and ascites may also be controlled by complete cytoreductive surgery and hyperthermic chemoperfusion. This aggressive surgical concept is limited to single carefully selected patients. In malignant ascites, intraperitoneal immunotherapy by catumaxomab is a novel and highly effective option, which controls ascites by targeted destruction of peritoneal cancer cells. CONCLUSION: Various options for treatment of pleural effusions and ascites are available. Careful evaluation of the individual patient is necessary to improve quality of life and survival.


Assuntos
Ascite/cirurgia , Neoplasias/cirurgia , Cuidados Paliativos/métodos , Derrame Pleural Maligno/cirurgia , Anticorpos Biespecíficos/administração & dosagem , Antineoplásicos/administração & dosagem , Quimioterapia do Câncer por Perfusão Regional , Tubos Torácicos , Terapia Combinada , Drenagem/métodos , Humanos , Hipertermia Induzida/métodos , Cirrose Hepática/cirurgia , Paracentese/métodos , Pleurodese/métodos , Derivação Portossistêmica Transjugular Intra-Hepática/métodos , Toracoscopia/métodos
2.
Cancer Treat Res ; 134: 483-91, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17633076

RESUMO

Intraperitoneal immunotherapy actually is a promising concept for treatment of peritoneal carcinomatosis for several reasons: The use of specifically engineered therapy in terms of antibodies or stimulated T lymphocytes against epithelial tumour antigens offers an elegant way to attack tumours on the peritoneal surface, as peritoneal cells have a mesenchymal origin. This is especially true for modern multimodal treatment concepts, were local compartment treatment together with systemic chemotherapy and (if possible) surgical tumour removal will be individually combined.


Assuntos
Carcinoma/terapia , Imunoterapia/métodos , Neoplasias Peritoneais/terapia , Anticorpos/uso terapêutico , Carcinoma/tratamento farmacológico , Citocinas/farmacologia , Citocinas/uso terapêutico , Humanos , Cavidade Peritoneal , Neoplasias Peritoneais/tratamento farmacológico , Peritônio/imunologia , Linfócitos T/efeitos dos fármacos
3.
Chirurg ; 86(4): 366-72, 2015 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-24969344

RESUMO

BACKGROUND: Appendicectomy (AE), the most frequent emergency surgical procedure, can be performed as a transvaginal hybrid natural orifice translumenal endoscopic surgery (NOTES) technique (TVAE). The question of feasibility also arises in cases of advanced inflammation with perforation. MATERIAL AND METHODS: Since May 2012 all female patients with suspected acute appendicitis were offered a TVAE as an alternative to the standard procedure. Preoperative, intraoperative and postoperative parameters were registered prospectively. RESULTS: Until October 2013 a total of 13 TVAEs had been performed. The median age of the patients was 41 years (range 20-76 years), median BMI was 23.1 (range 18.1-28.3 kg/m(2)) and the American Society of Anesthesiologists score (ASA) distribution (I/II/≥ III) was 8/5/0. Histology revealed three cases of perforated, one hemorrhagic necrotizing and seven phlegmonous appendicitis. Furthermore, there were two findings without inflammation, namely one neurogenic appendicopathy and one neuroendocrine tumor. For the three patients with perforated appendicitis, there was a trend for higher age (67.0 years versus 33.5 years, p=0.063) and a higher C-reactive protein (CRP) level on admission (134.4 mg/l versus 26.4 mg/l, p=0.043). Also, procedural time and hospital stay were longer (64 min versus 47 min, p=0.033 and 14 days versus 3 days, p=0.004, respectively). The former was mostly due to more extensive intraoperative flushing (volume 3000 ml versus 500 ml, p=0.013 and duration 13 min versus 2 min, p=0.011). None of the cases required conversion but two of the three postoperative complications occurred in patients with perforation, which also resulted in the longer hospital stay. CONCLUSION: Technically, TVAE seems feasible also in cases of perforated appendicitis. However, in these cases procedural time is prolonged due to more extensive flushing. Whether or not the longer hospital stay can be attributed to the perforation or if TVAE results in a higher rate of complications in cases of perforated appendicitis needs further evaluation.


Assuntos
Apendicectomia/métodos , Apendicite/cirurgia , Cirurgia Endoscópica por Orifício Natural/métodos , Adulto , Idoso , Emergências , Estudos de Viabilidade , Feminino , Humanos , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Umbigo , Vagina , Adulto Jovem
4.
Shock ; 8(6): 402-8, 1997 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9421852

RESUMO

Even though blood transfusion-associated immunomodulatory effects have been reported, the basic immune mechanism is still not understood. Data from studies on the clinical effects of allogeneic blood-induced immunosuppression are contradictory. However, there are indications that autologous blood transfusion is not immunologically neutral but has intrinsic immunomodulatory potential. Therefore we investigated in vivo different immunological mediators in 56 randomized patients of a study comparing autologous and allogeneic blood transfusion in colorectal cancer surgery. Soluble IL-2 receptor, which is an indicator of general immune activation and the following immunologic refractory phase, indicated immunosuppression was more elevated at the seventh postoperative day in patients with allogeneic transfusions (p = .013) and autologous transfusions (p = .0003). The immunologic determination of TNF-alpha showed a significant postoperative increase in patients with autologous transfusions only (p = .0031). However, postoperative increase of soluble TNF-receptors p55 and p75 was also significant in patients transfused with allogenic blood (p = .022; p = .0014). The response to tetanus toxoid vaccination, an indicator of humoral immunity, was higher in patients transfused with allogeneic rather than autologous blood (p = .082), whereas responses of patients with autologous transfusions were even lower than in nontransfused patients. The reciprocal was already found for cell-mediated immunity determined by epicutaneously tested delayed-type hypersensitivity-reactions. IL-10 levels, an indicator of cellular immunosuppression, were determined in 27 additional patients before operation, immediately postoperative, and at the seventh postoperative day. IL-10 was found elevated immediately postoperative in allogeneic (p = .011) and nontransfused patients only (p = .042). The data from this study substantiate recent findings of a different immunomodulatory potential of allogeneic and autologous blood transfusion. They furthermore support the hypothesis that autologous blood transfusion does not contain immunologically neutral effects of allogeneic blood, but itself exerts an immunomodulatory effect.


Assuntos
Formação de Anticorpos/imunologia , Transfusão de Sangue , Adjuvantes Imunológicos/sangue , Adulto , Idoso , Especificidade de Anticorpos , Transfusão de Sangue Autóloga , Neoplasias Colorretais/cirurgia , Cirurgia Colorretal , Citocinas/sangue , Feminino , Humanos , Imunoglobulinas/sangue , Imunoglobulinas/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Toxoide Tetânico/imunologia , Transplante Homólogo
5.
Chirurg ; 81(11): 999-1004, 2010 Nov.
Artigo em Alemão | MEDLINE | ID: mdl-20237747

RESUMO

BACKGROUND: The need for red blood cell units in cancer surgery is increasing. The role of the better immunological options, such as preoperative blood donation or intraoperative autologous blood salvage is not known. The aim of this survey was to clarify the transfusion setting and options for cancer patients in Germany. METHOD: A questionnaire was send to 90 directors of surgical departments in Germany. RESULTS: A total of 60 directors answered the questionnaire. In most cases the blood loss is compensated by allogenic blood transfusions. The possibility of preoperative blood donation exists in 85% of the hospitals and is offered in 3% for cancer patients. The intraoperative blood salvage is possible in 93% of the hospitals and 10% use this procedure without an additional purifying process for cancer patients. Of the hospitals 31% are able to irradiate blood collected intraoperatively, but only 11% use this for cancer patients. CONCLUSION: Perioperative blood loss is compensated by allogenic blood transfusion. The better immunological procedures, such as preoperative blood donation or intraoperative blood salvage, are not used because of the higher costs and the possible retransfusion of tumor cells.


Assuntos
Perda Sanguínea Cirúrgica/fisiopatologia , Transfusão de Sangue Autóloga , Transfusão de Sangue , Neoplasias do Sistema Digestório/cirurgia , Neoplasias Pulmonares/cirurgia , Recuperação de Sangue Operatório , Coleta de Dados , Neoplasias do Sistema Digestório/sangue , Alemanha , Hospitais Universitários , Humanos , Neoplasias Pulmonares/sangue , Inquéritos e Questionários
6.
Vox Sang ; 73(4): 237-45, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9407641

RESUMO

BACKGROUND AND OBJECTIVES: Immunosuppression associated with blood transfusion may influence postoperative infection rates. It may also affect the prognosis of patients treated surgically for colorectal cancer. To control this effect, study protocols have applied autologous blood donation programs, which are thought to be immunologically neutral. However, evidence has emerged that blood donation itself might have suppressive effects on natural killer (NK) cell activities. At present, there are no data available on the effects of autologous blood transfusion on NK or lymphokine-activated killer (LAK) cells. This might be of interest as LAK cells may be active in tumor control. MATERIALS AND METHODS: 26 patients who underwent surgical resection for colorectal cancer, were assigned at random into two groups: (1) autologous blood donation and transfusion, or (2) allogeneic blood transfusion. NK and LAK activities were determined before blood donation, at surgery, and on the 3rd and 8th postoperative day. RESULTS: Blood donation induced a small decrease in NK and LAK activities. The postoperative courses of the two groups differed. In the allogeneic group, NK activity (-50%, p = 0.018) and LAK activity decreased (-60.7%, p = 0.043), whereas in the autologous group the decline in LAK was less pronounced (-33.7%, p = 0.091), and their NK activity even increased (+17.4%, p = 0.315). NK activity was modulated differently in the two study groups (0.0036). Differences in LAK activities were found between the 3rd and 8th day postoperatively (p = 0.354). CONCLUSIONS: In patients receiving autologous blood transfusion, postoperative suppressed NK and LAK activities were modulated. This implies that autologous blood transfusion is not immunologically neutral, but has an intrinsic immunomodulatory potential.


Assuntos
Transfusão de Sangue Autóloga , Neoplasias Colorretais/cirurgia , Células Matadoras Ativadas por Linfocina/imunologia , Células Matadoras Naturais/imunologia , Idoso , Neoplasias Colorretais/imunologia , Feminino , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/imunologia , Transplante Homólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA